Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

Details 詳細情報について

• CRID

  1362544421361305728

• DOI

  10.1016/j.ijantimicag.2020.105954

• ISSN

  09248579

• Web Site

  https://api.elsevier.com/content/article/PII:S0924857920301047?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S0924857920301047?httpAccept=text/plain

• Data Source

  • Crossref